Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants - The Lancet

Our previous data showed early signs of waning effectiveness of the BNT162b2 (Pfizer–BioNTech) mRNA COVID-19 vaccine against omicron (B.1.1.529) variant-related hospital and emergency department admission 3 months or longer after receipt of a third dose in US…

We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2022 Elsevier In… [+173 chars]

full article...